Exposure to toxic heavy metals, such as lead, mercury, arsenic, and cadmium (Pb²⁺, Hg²⁺, As⁵⁺, As³⁺, and Cd²⁺), is a known contributor to neurological dysfunction. Although the individual neurotoxicity of these metals has been well established, their synergistic effects with endogenous neurotoxins such as glutamate remain insufficiently explored. In this study, we investigated neurotoxic effects of the combination of glutamate and heavy metals using the HT-22 hippocampal neuronal cell line. The cells were exposed to each heavy metal alone or in combination with glutamate at low [LCR; glutamate: heavy metal = 1:0.0025] and high [HCR; glutamate: heavy metal = 1:0.025] concentration ratios. Cell viability was measured by the MTT assay, and synergistic effects were quantitatively assessed by the Chou–Talalay method using CompuSyn software. The results showed that Pb²⁺ exhibited consistent synergistic effects with glutamate at both concentration ratios. In addition, Hg²⁺ and As⁵⁺ demonstrated synergistic effects with glutamate under high concentration conditions. These findings highlight that certain heavy metals can potentiate glutamate-induced neurotoxicity through synergistic mechanisms. This study provides quantitative evidence for the enhanced neurotoxic potential of environmental heavy metals when combined with endogenous excitotoxins such as glutamate.
Adenoviral vector vaccines were pivotal for COVID-19 control, but postmarketing safety surveillance has identified venous-predominant thrombotic risks not fully explained by platelet-centric mechanisms. We tested an RBC-associated hypothesis using an Ad5 vector-rAd/HA(PR8) rat model within a predefined sub-hemolytic window (<10% hemolysis). Ex vivo, we quantified RBC surface phosphatidylserine (PS) exposure, morphology remodeling by scanning electron microscopy, and microvesicle generation, all aligning with increased procoagulant activity. RBCs also exhibited dose-dependent increases in thrombin generation 4 h after intravenous exposure (108–109 OPU/Rat). In vivo, an inferior vena cava thrombosis model showed a pronounced, dose-responsive rise in thrombus burden, consistent with increased thrombogenic potential. Together, these integrated data provide experimental evidence consistent with RBC involvement under adenoviral exposure, supporting a biologically plausible link to the venous-predominant epidemiology observed during the COVID-19 vaccination era. Reported clinical adenoviral vaccine doses are of the same order of magnitude as the exposures tested here, supporting translational relevance while not implying inter-species or product equivalence. Incorporating RBC-focused endpoints, including PS exposure, morphology indices, microvesicle counts, and thrombin generation, into preclinical and early clinical assessments may enhance safety evaluation and inform vector design to mitigate venous thrombotic risk.